ANDA approval may boost Orchid Pharma

| Updated on May 14, 2019 Published on May 14, 2019


Orchid Pharma, erstwhile Orchid Chemicals and Pharmaceuticals Ltd, on Tuesday informed the exchanges that it has received abbreviated new drug application (ANDA) approval from the US FDA for Risedronate Sodium tablets USP, 30 mg and 35 mg. The drug (bisphosphonate) is used for the treatment and prevention of osteoporosis, the statement added. Shareholders of the loss-making pharma firm will closely monitor further developments.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on May 14, 2019
This article is closed for comments.
Please Email the Editor